ASH 2024 – Efstathios Kastritis
Efstathios Kastritis provides insights into the efficacy of ibrutinib-based treatments for Waldenström’s macroglobulinemia and discusses the current state of research on resistance mechanisms to BTK inhibitors and strategies to overcome them. He also reflects on how modern therapies have transformed real-world outcomes for patients, offering a comprehensive perspective on the evolving treatment landscape of Waldenström’s macroglobulinemia.
